Zacks Investment Research upgraded shares of VBI Vaccines (NASDAQ:VBIV) from a hold rating to a buy rating in a research note published on Saturday morning. Zacks Investment Research currently has $5.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “
VBIV has been the subject of several other reports. Canaccord Genuity assumed coverage on shares of VBI Vaccines in a research note on Wednesday, November 1st. They issued a buy rating and a $10.00 target price for the company. BidaskClub cut shares of VBI Vaccines from a hold rating to a sell rating in a research note on Thursday, December 14th. Finally, BMO Capital Markets assumed coverage on shares of VBI Vaccines in a research note on Wednesday, November 15th. They issued an outperform rating and a $11.00 target price for the company. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $8.75.
In other VBI Vaccines news, major shareholder Opko Health, Inc. bought 655,738 shares of VBI Vaccines stock in a transaction that occurred on Monday, October 30th. The shares were acquired at an average price of $3.05 per share, for a total transaction of $2,000,000.90. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive bought 3,100,000 shares of VBI Vaccines stock in a transaction that occurred on Thursday, October 26th. The shares were acquired at an average price of $3.05 per share, for a total transaction of $9,455,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 4,080,738 shares of company stock worth $12,480,151. 54.50% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of VBIV. Bank of Montreal Can lifted its holdings in shares of VBI Vaccines by 8.6% during the 2nd quarter. Bank of Montreal Can now owns 63,398 shares of the biopharmaceutical company’s stock valued at $277,000 after acquiring an additional 5,000 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in VBI Vaccines in the 2nd quarter worth $187,000. Bank of New York Mellon Corp acquired a new position in VBI Vaccines in the 2nd quarter worth $193,000. Teachers Advisors LLC acquired a new position in VBI Vaccines in the 2nd quarter worth $195,000. Finally, TIAA CREF Investment Management LLC acquired a new position in VBI Vaccines in the 2nd quarter worth $262,000. Institutional investors and hedge funds own 20.93% of the company’s stock.
WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/24/vbi-vaccines-vbiv-upgraded-by-zacks-investment-research-to-buy.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.